DESTINY-Lung04: First-Line Trastuzumab Deruxtecan Improves PFS in NSCLC
Daiichi Sankyo and AstraZeneca reported phase 3 DESTINY-Lung04 topline results. In 454 treatment-naive patients with HER2 exon 19/20 mutant advanced nonsquamous NSCLC, trastuzumab deruxtecan (Enhertu) 5.4 mg/kg improved progression-free survival versus SOC (platinum-pemetrexed plus pembrolizumab). The trial is ongoing for secondary endpoints including overall survival.
How this was made
The 30-second read
Why it matters
The article’s newest fact is statistically significant improvement in blinded independent central review PFS for first-line Enhertu versus SOC, with OS and other secondary endpoints pending.
Market read
First-line phase 3 PFS improvement is a meaningful clinical catalyst that can shift expectations for Enhertu’s potential label expansion in HER2-mutant NSCLC, but OS and other secondary endpoints remain outstanding.
What to watch
Open-label design and the comparator regimen (platinum-pemetrexed plus pembrolizumab) raise the bar for durability; the market may discount if investigator-assessed outcomes or response depth do not confirm central review.
Background
DESTINY-Lung04 is a phase 3, open-label trial in treatment-naive HER2 exon 19/20 mutant nonsquamous NSCLC comparing trastuzumab deruxtecan (Enhertu) versus platinum-pemetrexed plus pembrolizumab (SOC).
Ticker impact
AstraZeneca is partnering with Daiichi Sankyo to share DESTINY-Lung04 results with regulators after topline first-line PFS improvement for Enhertu.
Likely modest-to-positive reaction, tempered by the absence of OS and detailed efficacy metrics in the release.
The news is material clinical data (phase 3, first-line), but the article is topline and explicitly defers secondary endpoints to later.
Market effects
Reinforces momentum for HER2-directed antibody-drug conjugates in lung cancer, potentially lifting sentiment across ADC peers and HER2-targeted oncology programs.
Primarily impacts US-listed biotech/oncology sentiment via global trial read-through; direct regional effects are secondary.
Global regulatory and competitive positioning for HER2-mutant NSCLC treatment standards could shift as first-line data accumulates.
Counterpoint
Topline PFS without OS and without detailed effect size can overstate near-term value; investors may wait for secondary endpoints before repricing materially.
Key entities
- drugEnhertu (trastuzumab deruxtecan, T-DXd)
HER2-directed antibody-drug conjugate evaluated as first-line therapy in DESTINY-Lung04.
- clinical_trialDESTINY-Lung04 (NCT05048797)
Phase 3 study enrolling 454 treatment-naive patients with HER2 exon 19/20 mutant nonsquamous NSCLC.
- companyDaiichi Sankyo
Co-developer/partner announcing topline results and planning regulatory discussions.
- companyAstraZeneca
Co-developer/partner planning to share results with regulators.
